Compare CREG & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CREG | CVKD |
|---|---|---|
| Founded | N/A | 2022 |
| Country | China | United States |
| Employees | N/A | 5 |
| Industry | Power Generation | Medicinal Chemicals and Botanical Products |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.9M | 10.3M |
| IPO Year | 2019 | 2022 |
| Metric | CREG | CVKD |
|---|---|---|
| Price | $2.66 | $3.43 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | ★ 4.8M | 66.7K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.94 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $262,509.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.16 | $3.02 |
| 52 Week High | $2.66 | $14.64 |
| Indicator | CREG | CVKD |
|---|---|---|
| Relative Strength Index (RSI) | 86.32 | 29.69 |
| Support Level | $1.08 | N/A |
| Resistance Level | $2.66 | $5.99 |
| Average True Range (ATR) | 0.14 | 0.43 |
| MACD | 0.22 | -0.11 |
| Stochastic Oscillator | 82.63 | 11.08 |
Smart Powerr Corp is engaged in waste energy recycling and is a developer of energy efficiency solutions for various energy intensive industries in China. It uses Build-Operate-Transfer (BOT) model to provide energy saving and recovery facilities for multiple energy intensive industries in China. Its waste energy recycling projects allow customers which use substantial amounts of electricity to recapture previously wasted pressure, heat, and gas from their manufacturing processes to generate electricity. It provides a clean-technology and energy-efficient solution aimed at reducing the air pollution and energy shortage problems in China. The company's operations are conducted in one industry segment. All of its assets are located in the PRC.
Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.